ALVOCIDIB
Alvocidib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against cyclin-dependent kinase 2 and cyclin-dependent kinase 4.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
64 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myeloid leukemia acute | D015470 | — | C92.0 | 8 | 8 | — | — | — | 14 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 6 | 5 | — | — | — | 9 |
| Monocytic leukemia acute | D007948 | — | — | 2 | 4 | — | — | — | 6 |
| Myelomonocytic leukemia acute | D015479 | — | C92.5 | 2 | 4 | — | — | — | 6 |
| Myeloid leukemia | D007951 | — | C92 | 2 | 4 | — | — | — | 6 |
| Erythroblastic leukemia acute | D004915 | EFO_1001257 | C94.0 | 2 | 4 | — | — | — | 6 |
| Megakaryoblastic leukemia acute | D007947 | — | C94.2 | 2 | 3 | — | — | — | 5 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 5 | 1 | — | — | — | 5 |
| Waldenstrom macroglobulinemia | D008258 | HP_0005508 | C88.0 | 4 | 2 | — | — | — | 4 |
| Lymphoma | D008223 | — | C85.9 | 2 | 3 | — | — | — | 4 |
Show 29 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 18 | — | — | — | — | 18 |
| Anemia | D000740 | HP_0001903 | D64.9 | 2 | — | — | — | — | 2 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 2 | — | — | — | — | 2 |
| Leukemia | D007938 | — | C95 | 1 | — | — | — | — | 1 |
| Thrombocytopenia | D013921 | HP_0001873 | D69.6 | 1 | — | — | — | — | 1 |
| Male breast neoplasms | D018567 | — | — | 1 | — | — | — | — | 1 |
| Hairy cell leukemia | D007943 | — | C91.4 | 1 | — | — | — | — | 1 |
| Gastrointestinal stromal tumors | D046152 | EFO_0000505 | C49.A | 1 | — | — | — | — | 1 |
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | — | — | — | — | 1 |
| Small cell carcinoma | D018288 | — | — | 1 | — | — | — | — | 1 |
Show 10 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ALVOCIDIB |
| INN | alvocidib |
| Description | Alvocidib is a synthetic dihydroxyflavone that is 5,7-dihydroxyflavone which is substituted by a 3-hydroxy-1-methylpiperidin-4-yl group at position 8 and by a chlorine at the 2' position (the (-)-3S,4R stereoisomer). A cyclin-dependent kinase 9 (CDK9) inhibitor, it has been studied for the treatment of acute myeloid leukaemia, arthritis and atherosclerotic plaque formation. It has a role as an antineoplastic agent, an EC 2.7.11.22 (cyclin-dependent kinase) inhibitor, an antirheumatic drug and an apoptosis inducer. It is a dihydroxyflavone, a hydroxypiperidine, a member of monochlorobenzenes and a tertiary amino compound. It is a conjugate base of an alvocidib(1+). |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1 |
Identifiers
| PDB | — |
| CAS-ID | 146426-40-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL428690 |
| ChEBI ID | — |
| PubChem CID | 5287969 |
| DrugBank | DB03496 |
| UNII ID | 45AD6X575G (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
CCNT1
CCNT1
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 5,011 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
72 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use